Amendment to the Claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claims 1 to 17. (Cancelled)

18. (Withdrawn) A method for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

19. (Withdrawn) A method for the prevention and/or treatment of a medical condition selected from the group consisting of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies, and dementia pugilistica, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

20. (Withdrawn) The method according to claim 19, wherein the medical condition is Alzheimer's Disease.

21. (Withdrawn) A method for the prevention and/or treatment of a medical condition selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma, chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders,

hair loss, and pregnancy, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

22. (Withdrawn) A method for the prevention and/or treatment of a medical condition selected from the group consisting of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment, cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia, and androgenetic alopecia, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

23. (Withdrawn) A process for the preparation of a compound of formula Ia according to claim 1, the process comprising a step selected from the group consisting of:
a) reacting a compound of formula B, wherein L^1 is a leaving group, with a compound of formula C, wherein P, R^1, R^2, R^3, m, and n are as defined in claim 1, in a solvent at a temperature between +10°C and +150°C, to form the compound of formula Ia;



(B) (C) (Ia)

b) reacting a compound of formula XXV, wherein halo is halogen, with a compound of formula C, wherein R^1, R^2, R^4, R^5, and m are as defined in claim 1, in a solvent at a temperature between +10°C and +150°C, to form the compound of formula Ia;



(XXV) (C) (Ia)

c) reacting a compound of formula XXVII, wherein R^4 is C_{1-6}alkyl, with an amine of formula HNR^4R^5, wherein R^1, R^2, and R^5 are defined in claim 1, and wherein R^4 in the amine and in the compound of formula XXVII is the same or different, in a solvent in the presence of a reagent at a reaction temperature between 0°C and reflux, to form the compound of formula Ia;



(XXVII) (Ia)

d) reacting a compound of formula XXVII with an amine of formula R^4R^5NH, wherein R^4 is C_{1-6}alkyl and R^1, R^2, R^5, and m are defined in claim 1, and wherein R^4 in the amine and in the compound of formula XXVII is the same or different, neat or in a solvent, optionally in the presence of a base, at a temperature between -20°C and +150°C, to form the compound of formula Ia; and



(XXVII) (Ia)

e) reducing the N-oxide in a compound of formula XXVIII with a reagent in a solvent at a temperature between 0°C and +100°C, to form the compound of formula Ia,



(XXVIII) (Ia)

wherein R^1, R^2, R^4, R^5, and m are defined in claim 1.

24. (Withdrawn) A process for the preparation of a compound of formula Ib according to claim 1, the process comprising:

fluorinating a compound of formula Ia,



(Ia) **(Ib)**

in a solvent in the presence of a fluorinating reagent and a base at a reaction temperature between -40 °C and +80 °C, to form the compound of formula Ib, wherein R^1, R^2, R^3, m, and n are as defined in claim 1.

25. (Withdrawn) A compound according to formula XXV,



(XXV)

wherein:

Halo is halogen;

R^3 is selected from the group consisting of halogen, nitro, C_{1-6}alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $OC_{1-6}alkylNR^4R^5$, C_{0-6}alkylcyano, $C_{0-6}alkylCONR^4R^5$, $C_{0-6}alkyl(SO_2)NR^4R^5$, $C_{0-6}alkylNR^4R^5$, and X^1R^6;

X^1 is selected from the group consisting of a direct bond, O, $CONR^7R^8$, $SO_2NR^9R^{10}$, SO_2R^{11}, and $NR^{12}R^{13}$;

R^7, R^9, and R^{12} are each independently selected from hydrogen and C_{1-3}alkyl;

R^8, R^{10}, R^{11}, and R^{13} are each independently selected C_{0-4}alkyl groups;

R^6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms selected independently from N, O, and S, wherein:

the heterocyclic group is saturated or unsaturated,

the phenyl or 5-, 6- or 7-membered heterocyclic group is optionally fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O, and S, and

the phenyl or heterocyclic group is optionally substituted with one or two substituents selected from W; and

R^6 is linked to R^8, R^{10}, R^{11}, and R^{13}.

26. (Withdrawn) The compound according to claim 25, wherein R^3 is $C_{0\text{-}6}alkylNR^4R^5$; and n is 1.

27. (Withdrawn) A compound selected from the group consisting of:

1-[(6-Chloropyridin-3-yl)methyl]-4-methylpiperazine;

2-Chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide;

2-Chloro-5-(pyrrolidin-1-ylmethyl)pyridine 1-oxide;

1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methyl-1,4-diazepane;

2-Chloro-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridine 1-oxide;

1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N,N-dimethylpyrrolidin-3-amine;

2-Chloro-5-[(4-methylpiperidin-1-yl)methyl]pyridine 1-oxide;

1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-phenylpiperazine;

1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine;

3-[[(6-Chloro-1-oxidopyridin-3-yl)methyl](ethyl)amino]propanenitrile;

N-(4-Chlorobenzyl)-N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-methylamine;

N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-(2-furylmethyl)-N-methylamine;

N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-methyl-N-phenylamine;

5-(Azetidin-1-ylmethyl)-2-chloropyridine 1-oxide;

2-Chloro-5-[(3-methylpiperidin-1-yl)methyl]pyridine 1-oxide;

N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-cyclohexyl-N-methylamine; and

2-Chloro-5-(piperidin-1-ylmethyl)pyridine 1-oxide.

28. (Withdrawn) A compound according to formula B,



(B)

wherein:

P is a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O, and S, of which at least one heteroatom is nitrogen;

L^1 is a leaving group;

R^3 is selected from the group consisting of halogen, nitro, C_{1-6}alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $OC_{1-6}alkylNR^4R^5$, C_{0-6}alkylcyano, $C_{0-6}alkylCONR^4R^5$, $C_{0-6}alkyl(SO_2)NR^4R^5$, $C_{0-6}alkylNR^4R^5$, and X^1R^6;

X^1 is selected from the group consisting of a direct bond, O, $CONR^7R^8$, $SO_2NR^9R^{10}$, SO_2R^{11}, and $NR^{12}R^{13}$;

R^7, R^9, and R^{12} are each independently selected from hydrogen and C_{1-3}alkyl;

R^8, R^{10}, R^{11}, and R^{13} are each independently selected C_{0-4}alkyl groups;

R^6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein:

the heterocyclic group is saturated or unsaturated,

the phenyl or 5-, 6- or 7-membered heterocyclic group is optionally fused with a 5- or 6-membered saturated or unsaturated ring containing atoms independently selected from C, N, O, and S, and

the phenyl or heterocyclic group is optionally substituted with one or two substituents selected from W; and

R^6 is linked to R^8, R^{10}, R^{11}, and R^{13}.

29. (Withdrawn) The compound according to claim 28, wherein:

P is a pyridine or pyrimidine ring;

L^1 is a leaving group;

R^3 is selected from the group consisting of C_{0-6}alkylCONR^{4}R^5, C_{0-6}alkyl(SO_2)NR^{4}R^5, and C_{0-6}alkylNR^{4}R^5; and

n is 1.

30. (Withdrawn) A compound selected from the group consisting of:

2-Chloro-N-[2-(dimethylamino)ethyl]isonicotinamide;

1-(2-Chloroisonicotinoyl)-4-methylpiperazine;

6-Chloro-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide;

4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine;

1-Benzyl-4-[(6-chloropyridine-3-yl)sulfonyl]piperazine;

1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(3-methylbutyl)piperazine;

1-[(6-Chloropyridin-3-yl)sulfonyl]-4-isopropylpiperazine;

1-[(6-Chloropyridin-3-yl)sulfonyl]-4-ethylpiperazine;

1-[(5-Bromo-6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine;

6-Chloro-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;

6-Chloro-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide;

6-Chloro-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide;

6-Chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide;

1-[(6-Chloropyridin-3-yl)sulfonyl]-4-methyl-1,4-diazepane; and

4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine.

31. (Withdrawn) A compound according to formula C,



(C)

wherein:

R^1 is hydrogen;

R^2 is selected from the group consisting of halogen, nitro, C_{1-6}alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $OC_{1-6}alkylNR^4R^5$, C_{0-6}alkylcyano, $C_{0-6}alkylCONR^4R^5$, $C_{0-6}alkyl(SO_2)NR^4R^5$, $C_{0-6}alkylNR^4R^5$, and X^1R^6;

X^1 is selected from the group consisting of a direct bond, O, $CONR^7R^8$, $SO_2NR^9R^{10}$, SO_2R^{11}, and $NR^{12}R^{13}$;

R^7, R^9, and R^{12} are each independently selected from hydrogen and C_{1-3}alkyl;

R^8, R^{10}, R^{11}, and R^{13} are each independently selected C_{0-4}alkyl groups;

R^6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein:

the heterocyclic group is saturated or unsaturated,

the phenyl or 5-, 6- or 7-membered heterocyclic group is optionally fused with a 5- or 6-membered saturated or unsaturated ring containing atoms independently selected from C, N, O, and S, and

the phenyl or heterocyclic group is optionally substituted with one or two substituents selected from W; and

R^6 is linked to R^8, R^{10}, R^{11}, and R^{13}.

32. (Withdrawn) The compound according to claim 31, wherein:

R^1 is hydrogen;

R^2 is selected from halogen and X^1R^6;

X^1 is a direct bond;

R^6 is a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S; and

m is 1 or 2.

33. (Withdrawn) A compound selected from the group consisting of:

5,6-Dibromo-1,3-dihydroindol-2-one;

5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one;

5-Thien-2-yl-1,3-dihydro-2H-indol-2-one;

5-(2-Furyl)-1,3-dihydro-2H-indol-2-one;

5-(1,3-Oxazol-5-yl)-1,3-dihydro-2H-indol-2-one;

5-(1,3-Thiazol-4-yl)-1,3-dihydro-2H-indol-2-one; and

5-(2-Methyl-1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one.

34 to 42. (Cancelled)

43. (Withdrawn) The process according to claim 23, wherein L^1 is a halogen.

44. (Withdrawn) The process according to claim 43, wherein the halogen is fluorine, chlorine, or bromine.

45. (Withdrawn) The process according to claim 23, wherein the halogen in process b) is fluorine, chlorine, or bromine.

46. (Withdrawn) The compound according to claim 28, wherein the leaving group is a halogen.

47. (Withdrawn) The compound according to claim 45, wherein the halogen is fluorine, chlorine, or bromine.

48. (Withdrawn) The compound according to claim 29, wherein the leaving group is a halogen.

49. (Withdrawn) The compound according to claim 47, wherein the halogen is chlorine.

50. (Currently amended) A compound of formula Ia,



(Ia)

wherein the compound is in the form base or a pharmaceutically acceptable salt thereof, and wherein:

P is a 6-membered ring containing one nitrogen;

R^1 is hydrogen;

R^2 is ~~C_{0-6}alkylcyano~~ C_{0-6}alkylcyano;

R^3 is C_{0-6}alkylNR^4R^5;

m is 1;

n is 1;

R^4 is selected from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, C_{1-6}alkyl$NR^{14}R^{15}$, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;

R^5 is selected from the group consisting of hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, C_{0-6}alkylheteroaryl, and C_{1-6}alkyl$NR^{14}R^{15}$;

or R^4 and R^5 together with the N to which they are attached may form a 6-membered heterocyclic group containing one nitrogen and one oxygen; and

wherein any C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{0-6}alkylC_{3-6}cycloalkyl, C_{0-6}alkylaryl, and C_{0-6}alkylheteroaryl group defined under R^2 to R^5 is optionally substituted by one or more groups Z;

R^{14} and R^{15} are independently selected from hydrogen, C_{1-6}alkyl, and C_{0-6}alkylC_{3-6}cycloalkyl, wherein R^{14} and R^{15} optionally together form a 5- or 6-membered heterocyclic group containing

one or more heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;

Z is independently selected from the group consisting of oxo, halogen, nitro, CN, OR^{16}, C_{1-6}alkyl, C_{0-6}alkylaryl, C_{0-6}alkylC_{3-6}cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC_{1-6}alkyl$NR^{16}R^{17}$, $NR^{16}R^{17}$, $CONR^{16}R^{17}$, $NR^{16}(CO)R^{17}$, $O(CO)C_{1-6}$alkyl, $(CO)OC_{1-6}$alkyl, COR^{16}, $(SO_2)NR^{16}R^{17}$, SO_2R^{16}, SOR^{16}, $(CO)C_{1-6}$alkyl$NR^{16}R^{17}$, $(SO_2)C_{1-6}$alkyl$NR^{16}R^{17}$, phenyl, heteroaryl, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, heteroaryl, and heterocyclic groups are optionally substituted by a group Y;

Y is selected from the group consisting of oxo, halogen, nitro, CN, OR^{16}, C_{1-6}alkyl, C_{0-6}alkylaryl, C_{0-6}alkylC_{3-6}cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC_{1-6}alkyl$NR^{16}R^{17}$, $NR^{16}R^{17}$, $CONR^{16}R^{17}$, $NR^{16}(CO)R^{17}$, $O(CO)C_{1-6}$alkyl, $(CO)OC_{1-6}$alkyl, COR^{16}, $(SO_2)NR^{16}R^{17}$, SO_2R^{16}, SOR^{16}, $(CO)C_{1-6}$alkyl$NR^{16}R^{17}$, $(SO_2)C_{1-6}$alkyl$NR^{16}R^{17}$, phenyl, C_{0-6}alkylaryl, and heteroaryl, wherein the phenyl, C_{0-6}alkylaryl, and heteroaryl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, CN, OR^{16}, C_{1-6}alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, and trifluoromethoxy;

R^{16} and R^{17} are independently selected from hydrogen and C_{1-6}alkyl, and

wherein R^{16} and R^{17} optionally together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms independently selected from N, O, and S.

51. (Previously presented) A compound according to claim 50, wherein:

R^5 is C_{1-6}alkyl$NR^{14}R^{15}$, and

R^4 is selected from hydrogen, C_{1-6}alkyl; or

R^4 and R^5 together with the N to which they are attached form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

and wherein R^{14} and R^{15} may together form a 5-membered heterocyclic group containing one or more heteroatoms, selected independently from N, and O ;

Y is selected from C_{1-6}alkyl, C_{0-6}alkylaryl, $NR^{16}R^{17}$, phenyl, wherein the phenyl may be optionally substituted with nitro and trifluoromethyl;
wherein R^{16} and R^{17} may together form a 5-membered heterocyclic group containing one N heteroatom.

52. (Previously presented) A compound according to claim 50, wherein P is pyridyl; R^2 is CN; R^3 is C_{0-6}alkylNR^4R^5; wherein R^4 and R^5 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O.

53. (Previously presented) A compound according to claim 52, wherein R^4 and R^5 together form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O.

54. (Previously presented) A compound selected from:
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-5-carbonitrile;
3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]methyl}pyridin-2-yl)-2-hydroxy-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-[5-(Azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
3-[5-(Morpholin-4-ylcarbonyl)pyridin-2-yl]-5-nitro-1*H*-indol-2-ol, or
2-Hydroxy-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
or a pharmaceutically acceptable salt thereof.

55. (Previously presented) A compound selected from:
2-Hydroxy-3-{4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indol-2-ol;
6-Chloro-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indol-2-ol;
6-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
5-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
3-Fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-6-carbonitrile;
3-{5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carbonitrile;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-thien-2-yl-1*H*-indol-2-ol;
5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
3-{3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-nitro-1*H*-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1*H*-indol-2-ol;
6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-(2-morpholin-4-ylethyl)nicotinamide;
6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-methyl-*N*-(1-methylpiperidin-4-yl)nicotinamide;
5-Nitro-3-{5-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indol-2-ol;
3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}pyridin-2-yl)-5-nitro-1*H*-indol-2-ol;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(2-methyl-1,3-thiazol-4-yl)-1*H*-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1*H*-indol-2-ol;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile;
5,6-Dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol, or
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile;
or a pharmaceutically acceptable salt thereof.

56. (Previously presented) A hydrochloride salt of a compound according to claim 55.

57. (Previously presented) 6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-(2-pyrollindin-1-ylethyl)nicotinamide;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide;
2-Hydroxy-3-(5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-thiazol-4-yl)-1*H*-indol-2-ol, or
3-{5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-5-nitro-1*H*-indol-2-ol;
or a pharmaceutically acceptable salt thereof.

58. (Previously presented) A fumarate salt of a compound according to claim 57.

59. (Previously presented) A compound that is 2-Hydroxy-3-{5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.

60. (Previously presented) A compound that is 2-Hydroxy-3-[5-({4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-1-yl}methyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.

61. (Previously presented) A compound that is 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.

62. (Previously presented) A compound that is 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-pyridin-3-yl-1*H*-indol-2-ol or a pharmaceutically acceptable salt thereof.

63. (Previously presented) A compound that is 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-oxazol-5-yl)-1*H*-indol-2-ol or a pharmaceutically acceptable salt thereof.

64. (Previously presented) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 54-63 in association with at least one pharmaceutically acceptable carrier or diluent.